Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SFOSF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.23 Med: 5.01 Max: 12.93
Current: 3.73
During the past 13 years, Shanghai Fosun Pharmaceutical (Group) Co's highest Price to Tangible Book Ratio was 12.93. The lowest was 3.23. And the median was 5.01.
SFOSF's Price-to-Tangible-Book is ranked worse than 68.1% of 837
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs SFOSF: 3.73
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Shanghai Fosun Pharmaceutical (Group) Co Price-to-Tangible-Book Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Price-to-Tangible-Book Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Price-to-Tangible-Book of 2.49 as of Sep. 07, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #570 out of 837 companies in the Drug Manufacturers industry, placing it in the top 68.1%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Tangible-Book too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Price-to-Tangible-Book is 2.49. The Drug Manufacturers industry median Price-to-Tangible-Book is 2.30. Shanghai Fosun Pharmaceutical (Group) Co's value of 2.49 is 8.3% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #570 out of 837 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Price-to-Tangible-Book compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #570 out of 837 companies for Price-to-Tangible-Book. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.30. Shanghai Fosun Pharmaceutical (Group) Co's value of 2.49 is 8.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.30, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Price-to-Tangible-Book of 2.49 is 8.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Price-to-Tangible-Book is 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Fairly Valued. The stock's GF Value™ is $2.39, compared to a current price of $2.20 — trading 7.9% below its estimated fair value. The current Price-to-Tangible-Book is 2.49 and 8.3% above the Drug Manufacturers industry median of 2.30. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Price-to-Tangible-Book is 2.49 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 7.9% below its estimated GF Value™ of $2.39.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Fairly Valued.
Key valuation signals for SFOSF:
Price-to-Tangible-Book: 2.49
GF Value™: $2.39 vs. price of $2.20 (7.9% below fair value)
Industry Position: 8.3% above the Drug Manufacturers median (#570 of 837)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
72GF Score
Get the complete analysis for SFOSF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
